Future Perspectives of Bisphosphonates in Maxillofacial, Dental, and Medical Practice

  • Ralf Smeets
  • Henning Hanken
  • Ole Jung
  • Max Heiland
Chapter
First Online:

Abstract

Today, bisphosphonates are already used in a variety of indications, which by far exceed the commonly known applications. Closely related to their anorganic compound pyrophosphate, organic bisphosphonates are already used in everyday products like toothpastes and reagents for anticalculus and anti-calcification purposes. Besides that, bisphosphonates were successfully applied within experimental, animal, and clinical trial studies for dental socket preservations, periodontitis, and periimplantitis. Thereby, among other positive aspects like distinctive antibacterial profiles, more bone formation and fewer bone resorption were detected. Several other conditions commonly seen in oral and maxillofacial surgery might also benefit from administrations of antiresorptive drugs. In addition, bisphosphonates can also be successfully administered in uranyl intoxications as well as for hard and soft tissue calcifications. The primary aim of the ongoing research in this field can be defined in the detection of the ideal dose-effect relationship of different bisphosphonates when applied intravenously, orally, or topically.

Keywords

Bisphosphonate Pyrophosphate Applications Tissue engineering Periodontitis Periimplantitis Socket preservation Uranyl intoxication 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Abtahi J, Agholme F, Aspenberg P. Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. Int J Oral Maxillofac Surg. 2013;42(5):632–6. PubMed PMID: 23499148.PubMedGoogle Scholar
  2. 2.
    Abtahi J, Tengvall P, Aspenberg P. Bisphosphonate coating might improve fixation of dental implants in the maxilla: a pilot study. Int J Oral Maxillofac Surg. 2010;39(7):673–7. PubMed PMID: 20452185.PubMedGoogle Scholar
  3. 3.
    Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50(5):1148–51. PubMed PMID: 22348981.PubMedGoogle Scholar
  4. 4.
    Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res. 2012;27(10):2130–43. PubMed PMID: 22623376.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Aguirre JI, Altman MK, Vanegas SM, Franz SE, Bassit ACF, Wronski TJ. Effects of alendronate on bone healing after tooth extraction in rats. Oral Dis. 2010;16(7):674–85. PubMed PMID: 20846154.PubMedGoogle Scholar
  6. 6.
    Allen MR, Kubek DJ, Burr DB, Ruggiero SL, Chu TG. Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int. 2011;22(2):693–702. PubMed PMID: 20458574.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Armstrong DJ, Wright SA, Coward SM, Finch MB. Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. Ann Rheum Dis. 2006;65(7):976–7. PubMed PMID: 16769790.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013;33(9):3917–24. PubMed PMID: 24023329.PubMedGoogle Scholar
  9. 9.
    Bereket A, Erdogan T. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics. 2003;111(4 Pt 1):899–901. PubMed PMID: 12671131.PubMedGoogle Scholar
  10. 10.
    Bolland MJ, Cundy T. Paget’s disease of bone: clinical review and update. J Clin Pathol. 2013;66(11):924–7. PubMed PMID: 24043712.PubMedGoogle Scholar
  11. 11.
    Bozal CB, Martinez AB, Cabrini RL, Ubios AM. Effect of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) on endochondral ossification lesions induced by a lethal oral dose of uranyl nitrate. Arch Toxicol. 2005;79(8):475–81. PubMed PMID: 15798912.PubMedGoogle Scholar
  12. 12.
    Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol. 1992;63(10):825–30. PubMed PMID: 1328593.PubMedGoogle Scholar
  13. 13.
    Buduneli E, Buduneli N, Vardar-Sengül S, Kardeşler L, Atilla G, Lappin D, et al. Systemic low-dose doxycycline and alendronate administration and serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats. J Periodontol. 2005;76(11):1927–33. PubMed PMID: 16274312.PubMedGoogle Scholar
  14. 14.
    Buduneli E, Vardar S, Buduneli N, Berdeli AH, Türkoğlu O, Başkesen A, et al. Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. J Periodontol. 2004;75(11):1516–23. PubMed PMID: 15633329.PubMedGoogle Scholar
  15. 15.
    Cetinkaya BO, Keles GC, Ayas B, Gurgor P. Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. J Periodontol. 2008;79(10):1950–61. PubMed PMID: 18834251.PubMedGoogle Scholar
  16. 16.
    Chapurlat RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M, Mantyh P. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;7 Suppl 1:S3. PubMed PMID: 22640953.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Choi SC, Kwon Y, Kim KC, Kim G. The effects of topical application of bisphosphonates on replanted rat molars. Dent Traumatol. 2010;26(6):476–80. PubMed PMID: 21078072.PubMedGoogle Scholar
  18. 18.
    Cundy T. Recent advances in osteogenesis imperfecta. Calcif Tissue Int. 2012;90(6):439–49. PubMed PMID: 22451222.PubMedGoogle Scholar
  19. 19.
    D’Eufemia P, Finocchiaro R, Villani C, Zambrano A, Lodato V, Palombaro M, et al. Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment. Pediatr Res. 2014;75(5):626–30.PubMedGoogle Scholar
  20. 20.
    Duarte PM, de Assis DR, Casati MZ, Sallum AW, Sallum EA, Nociti FH. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol. 2004;75(9):1196–202. PubMed PMID: 15515333.PubMedGoogle Scholar
  21. 21.
    El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol. 2003;5(1):5–10. PubMed PMID: 12666950.PubMedGoogle Scholar
  22. 22.
    Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 1991;42(6):919–44. PubMed PMID: 1724640.PubMedGoogle Scholar
  23. 23.
    Fleisch H. Bisphosphonates: pharmacology. Semin Arthritis Rheum. 1994;23(4):261–2. PubMed PMID: 8009246.PubMedGoogle Scholar
  24. 24.
    Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4(1):30–4. PubMed PMID: 11879557.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J. 2003;12 Suppl 2:S142–6. PubMed PMID: 13680318.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Fleisch H. Einführung in die Bisphosphonate. Geschichte und Wirkungsmechanismen. Orthopade. 2007;36(2):103–4, 106–9. PubMed PMID: 17277961.PubMedGoogle Scholar
  27. 27.
    Fukuda S. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem. 2005;12(23):2765–70. PubMed PMID: 16305471.PubMedGoogle Scholar
  28. 28.
    Fukuda S, Ikeda M, Nakamura M, Katoh A, Yan X, Xie Y, et al. The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats. Hemoglobin. 2008;32(1–2):191–8. PubMed PMID: 18274996.PubMedGoogle Scholar
  29. 29.
    Fukuda S, Ikeda M, Nakamura M, Yan X, Xie Y. Effects of pH on du intake and removal by CBMIDA and EHBP. Health Phys. 2007;92(1):10–4. PubMed PMID: 17164594.PubMedGoogle Scholar
  30. 30.
    Furlaneto FAC, Nunes NLT, Oliveira Filho IL, Frota NPR, Yamamoto KO, Lisboa MRP, et al. Effects of locally-administered tiludronic acid on experimental periodontitis in rats. J Periodontol. 2014;85(9):1291–301.PubMedGoogle Scholar
  31. 31.
    Gerard DA, Carlson ER, Gotcher JE, Pickett DO. Early inhibitory effects of zoledronic acid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein. J Oral Maxillofac Surg. 2014;72(1):61–6. PubMed PMID: 23891015.PubMedGoogle Scholar
  32. 32.
    Göcmen A, Toppare MF, Kiper N, Büyükpamukcu N. Treatment of pulmonary alveolar microlithiasis with a diphosphonate–preliminary results of a case. Respiration. 1992;59(4):250–2. PubMed PMID: 1485012.PubMedGoogle Scholar
  33. 33.
    Goes P, Melo IM, Dutra CS, Lima APS, Lima V. Effect of alendronate on bone-specific alkaline phosphatase on periodontal bone loss in rats. Arch Oral Biol. 2012;57(11):1537–44. PubMed PMID: 23062673.PubMedGoogle Scholar
  34. 34.
    Goes P, Melo IM, Silva LMCM, Benevides NMB, Alencar NMN, Ribeiro RA, et al. Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats. J Periodontal Res. 2014;49(1):45–54. PubMed PMID: 23742139.PubMedGoogle Scholar
  35. 35.
    Graziani F, Rosini S, Cei S, La Ferla F, Gabriele M. The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial. J Craniofac Surg. 2008;19(4):1061–6. PubMed PMID: 18650733.PubMedGoogle Scholar
  36. 36.
    Hatano H, Shigeishi H, Higashikawa K, Shimasue H, Nishi H, Oiwa H, et al. A case of SAPHO syndrome with diffuse sclerosing osteomyelitis of the mandible treated successfully with prednisolone and bisphosphonate. J Oral Maxillofac Surg. 2012;70(3):626–31. PubMed PMID: 21816533.PubMedGoogle Scholar
  37. 37.
    Henge-Napoli MH, Ansoborlo E, Chazel V, Houpert P, Paquet F, Gourmelon P. Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Int J Radiat Biol. 1999;75(11):1473–7. PubMed PMID: 10597920.PubMedGoogle Scholar
  38. 38.
    Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2013;4(4):e1. PubMed PMID: 24478911.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Huang MS, Sage AP, Lu J, Demer LL, Tintut Y. Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun. 2008;374(3):553–8. PubMed PMID: 18655772.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Jee J, Lee W, Lee BD. The influence of alendronate on the healing of extraction sockets of ovariectomized rats assessed by in vivo micro-computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(2):e47–53. PubMed PMID: 20591699.PubMedGoogle Scholar
  41. 41.
    Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol. 2007;9(3):70–6. PubMed PMID: 17715838.PubMedGoogle Scholar
  42. 42.
    Kim J, Park Y, Li Z, Shim J, Moon H, Jung H, et al. Effect of alendronate on healing of extraction sockets and healing around implants. Oral Dis. 2011;17(7):705–11. PubMed PMID: 21771209.PubMedGoogle Scholar
  43. 43.
    Kivelä-Rajamäki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res. 2003;38(6):583–90. PubMed PMID: 14632921.PubMedGoogle Scholar
  44. 44.
    Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010;28(2):165–75. PubMed PMID: 19882100.PubMedGoogle Scholar
  45. 45.
    Koch G, Bergmann-Arnadottir I, Bjarnason S, Finnbogason S, Höskuldsson O, Karlsson R. Caries-preventive effect of fluoride dentifrices with and without anticalculus agents: a 3-year controlled clinical trial. Caries Res. 1990;24(1):72–9. PubMed PMID: 2403486.PubMedGoogle Scholar
  46. 46.
    Kuroshima S, Mecano RB, Tanoue R, Koi K, Yamashita J. Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy. J Periodontol. 2014;85(1):24–33. PubMed PMID: 23688101.PubMedGoogle Scholar
  47. 47.
    Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang H, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005;76(7):1113–22. PubMed PMID: 16018754.PubMedGoogle Scholar
  48. 48.
    de Lange J, Rosenberg AJ, van den Akker HP, Koole R, Wirds JJ, van den Berg H. Treatment of central giant cell granuloma of the jaw with calcitonin. Int J Oral Maxillofac Surg. 1999;28(5):372–6. PubMed PMID: 10535540.PubMedGoogle Scholar
  49. 49.
    Le Goff B, Berthelot J, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des. 2010;16(27):3045–52. PubMed PMID: 20722620.PubMedGoogle Scholar
  50. 50.
    Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008;73(9):1024–30. PubMed PMID: 18288101.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Mäkitie AA, Törnwall J, Mäkitie O. Bisphosphonate treatment in craniofacial fibrous dysplasia–a case report and review of the literature. Clin Rheumatol. 2008;27(6):809–12. PubMed PMID: 18247080.PubMedGoogle Scholar
  52. 52.
    Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology (Oxford). 2002;41(2):231–3. PubMed PMID: 11886977.Google Scholar
  53. 53.
    Martínez AB, Cabrini RL, Ubios AM. Orally administered ethane-1-hydroxy-1,1-biphosphonate reduces the lethal effect of oral uranium poisoning. Health Phys. 2000;78(6):668–71. PubMed PMID: 10832926.PubMedGoogle Scholar
  54. 54.
    Martinez AB, Mandalunis PM, Bozal CB, Cabrini RL, Ubios AM. Renal function in mice poisoned with oral uranium and treated with ethane-1-hydroxy-1,1-bisphosphonate (EHBP). Health Phys. 2003;85(3):343–7. PubMed PMID: 12938724.PubMedGoogle Scholar
  55. 55.
    Maruotti N, Corrado A, Neve A, Cantatore FP. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012;68(7):1013–8. PubMed PMID: 22318756.PubMedGoogle Scholar
  56. 56.
    Menezes AMA, Rocha FAC, Chaves HV, Carvalho CBM, Ribeiro RA, Brito GAC. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. J Periodontol. 2005;76(11):1901–9. PubMed PMID: 16274309.PubMedGoogle Scholar
  57. 57.
    Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol. 1999;70(2):151–8. PubMed PMID: 10102552.PubMedGoogle Scholar
  58. 58.
    Mitsuta T, Horiuchi H, Shinoda H. Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. J Periodontol. 2002;73(5):479–86. PubMed PMID: 12027248.PubMedGoogle Scholar
  59. 59.
    Monte GU, Drager LF, Souza FS, Avila LF, Parga Filho JR, César LAM, et al. Magnetic resonance vs technetium-99m pyrophosphate scintigraphy in the detection of perioperative myocardial necrosis. Arq Bras Cardiol. 2008;91(2):113–8. PubMed PMID: 18709263.PubMedGoogle Scholar
  60. 60.
    Moon H, Yun Y, Han C, Kim MS, Kim SE, Bae MS, et al. Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function. Biochem Biophys Res Commun. 2011;413(2):194–200. PubMed PMID: 21888898.PubMedGoogle Scholar
  61. 61.
    Mori GG, Janjacomo DM, Nunes DC, Castilho LR. Effect of zoledronic acid used in the root surface treatment of late replanted teeth: a study in rats. Braz Dent J. 2010;21(5):452–7. PubMed PMID: 21180803.PubMedGoogle Scholar
  62. 62.
    Nakaya H, Osawa G, Iwasaki N, Cochran DL, Kamoi K, Oates TW. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol. 2000;71(7):1158–66. PubMed PMID: 10960024.PubMedGoogle Scholar
  63. 63.
    O’Neill WC, Lomashvili KA, Malluche HH, Faugere M, Riser BL. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int. 2011;79(5):512–7. PubMed PMID: 21124302.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Otto S, Pautke C, Hafner S, Hesse R, Reichardt LF, Mast G, et al. Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases. Craniomaxillofac Trauma Reconstr. 2013;6(3):147–54. PubMed PMID: 24436752.PubMedCentralPubMedGoogle Scholar
  65. 65.
    O’uchi N, Nishikawa H, Yoshino T, Kanoh H, Motoie H, Nishimori E, et al. Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs. J Periodontal Res. 1998;33(4):196–204. PubMed PMID: 9689615.PubMedGoogle Scholar
  66. 66.
    Ozdemir SP, Kurtiş B, Tüter G, Bozkurt Ş, Gültekin SE, Sengüven B, et al. Effects of low-dose doxycycline and bisphosphonate clodronate on alveolar bone loss and gingival levels of matrix metalloproteinase-9 and interleukin-1β in rats with diabetes: a histomorphometric and immunohistochemical study. J Periodontol. 2012;83(9):1172–82. PubMed PMID: 22220769.PubMedGoogle Scholar
  67. 67.
    Pfarrer AM, White DJ, Featherstone JD. Anticaries profile qualification of an improved whitening dentifrice. J Clin Dent. 2001;12(2):30–3. PubMed PMID: 11476010.PubMedGoogle Scholar
  68. 68.
    Pradeep AR, Kumari M, Rao NS, Naik SB. 1% alendronate gel as local drug delivery in the treatment of Class II furcation defects: a randomized controlled clinical trial. J Periodontol. 2013;84(3):307–15. PubMed PMID: 22554293.PubMedGoogle Scholar
  69. 69.
    Pradeep AR, Sharma A, Rao NS, Bajaj P, Naik SB, Kumari M. Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial. J Periodontol. 2012;83(10):1322–8. PubMed PMID: 22264208.PubMedGoogle Scholar
  70. 70.
    Price U, Le HT, Powell SE, Schmid MJ, Marx DB, Zhang Y, et al. Effects of local simvastatin-alendronate conjugate in preventing periodontitis bone loss. J Periodontal Res. 2013;48(5):541–8. PubMed PMID: 23278592.PubMedGoogle Scholar
  71. 71.
    Reddy GT, Kumar TMP, Veena. Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv. 2005;12(4):217–22. PubMed PMID: 16044536.PubMedGoogle Scholar
  72. 72.
    Reddy MS, Weatherford TW, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturally-occurring periodontitis in beagle dogs. J Periodontol. 1995;66(3):211–7. PubMed PMID: 7776166.PubMedGoogle Scholar
  73. 73.
    Reid IR. Pharmacotherapy of Paget’s disease of bone. Expert Opin Pharmacother. 2012;13(5):637–46. PubMed PMID: 22339140.PubMedGoogle Scholar
  74. 74.
    Rocha M, Nava LE, La Vázquez de Torre C, Sánchez-Márin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol. 2001;72(2):204–9. PubMed PMID: 11288794.PubMedGoogle Scholar
  75. 75.
    Said F, Ghoul-Mazgar S, Khemiss F, El Ayeb H, Saidane D, Berdal A, et al. The effect of etidronate on the periodontium of ovariectomized rats. J Periodontol. 2012;83(8):1063–8. PubMed PMID: 22166164.PubMedGoogle Scholar
  76. 76.
    Samdancioglu S, Calis S, Sumnu M, Atilla Hincal A. Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis. Drug Dev Ind Pharm. 2006;32(4):473–81. PubMed PMID: 16638686.PubMedGoogle Scholar
  77. 77.
    Schneider VS, LeBlanc A, Huntoon CL. Prevention of space flight induced soft tissue calcification and disuse osteoporosis. Acta Astronaut. 1993;29(2):139–40. PubMed PMID: 11543594.PubMedGoogle Scholar
  78. 78.
    Seton M. Paget disease of bone: diagnosis and drug therapy. Cleve Clin J Med. 2013;80(7):452–62. PubMed PMID: 23821690.PubMedGoogle Scholar
  79. 79.
    Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial. J Periodontol. 2012;83(1):11–8. PubMed PMID: 21542734.PubMedGoogle Scholar
  80. 80.
    Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial. J Periodontol. 2012;83(1):19–26. PubMed PMID: 21609254.PubMedGoogle Scholar
  81. 81.
    Shibata T, Komatsu K, Shimada A, Shimoda S, Oida S, Kawasaki K, et al. Effects of alendronate on restoration of biomechanical properties of periodontium in replanted rat molars. J Periodontal Res. 2004;39(6):405–14. PubMed PMID: 15491345.PubMedGoogle Scholar
  82. 82.
    Shibutani T, Inuduka A, Horiki I, Luan Q, Iwayama Y. Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs. Clin Oral Implants Res. 2001;12(2):109–14. PubMed PMID: 11251659.PubMedGoogle Scholar
  83. 83.
    Shinoda H, Takeyama S, Suzuki K, Murakami S, Yamada S. Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis. J Pharmacol Sci. 2008;106(4):555–8. PubMed PMID: 18431039.PubMedGoogle Scholar
  84. 84.
    Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res. 1995;30(4):277–84. PubMed PMID: 7562325.PubMedGoogle Scholar
  85. 85.
    Shukla G, Tiwari AK, Sinha D, Srivastava R, Cahndra H, Mishra AK. Synthesis and assessment of 99mTc chelate-conjugated alendronate for development of specific radiopharmaceuticals. Cancer Biother Radiopharm. 2009;24(2):209–14. PubMed PMID: 19409043.PubMedGoogle Scholar
  86. 86.
    Sikder MNH, Itoh M, Iwatsuki N, Shinoda H. Inhibitory effect of a novel bisphosphonate, TRK-530, on dental calculus formation in rats. J Periodontol. 2004;75(4):537–45. PubMed PMID: 15152817.PubMedGoogle Scholar
  87. 87.
    Silverman SL. Bisphosphonate use in conditions other than osteoporosis. Ann N Y Acad Sci. 2011;1218:33–7. PubMed PMID: 20946575.PubMedGoogle Scholar
  88. 88.
    Soubrier M, Dubost JJ, Ristori JM, Sauvezie B, Bussière JL. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(6):637–40. PubMed PMID: 11740481.PubMedGoogle Scholar
  89. 89.
    Stadelmann VA, Bonnet N, Pioletti DP. Combined effects of zoledronate and mechanical stimulation on bone adaptation in an axially loaded mouse tibia. Clin Biomech (Bristol, Avon). 2011;26(1):101–5. PubMed PMID: 20869796.Google Scholar
  90. 90.
    Stadelmann VA, Gauthier O, Terrier A, Bouler JM, Pioletti DP. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater. 2008;16:10–6. PubMed PMID: 18671203.PubMedGoogle Scholar
  91. 91.
    Stadelmann VA, Terrier A, Gauthier O, Bouler J, Pioletti DP. Prediction of bone density around orthopedic implants delivering bisphosphonate. J Biomech. 2009;42(9):1206–11. PubMed PMID: 19380139.PubMedGoogle Scholar
  92. 92.
    Takaishi Y, Ikeo T, Miki T, Nishizawa Y, Morii H. Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year follow-up of four patients. J Int Med Res. 2003;31(6):575–84. PubMed PMID: 14708423.PubMedGoogle Scholar
  93. 93.
    Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res. 1997;76(9):1529–37. PubMed PMID: 9294486.PubMedGoogle Scholar
  94. 94.
    Toksvig-Larsen S, Aspenberg P. Bisphosphonate-coated external fixation pins appear similar to hydroxyapatite-coated pins in the tibial metaphysis and to uncoated pins in the shaft. Acta Orthop. 2013;84(3):314–8. PubMed PMID: 23621808.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Tsuchimochi M, Higashino N, Okano A, Kato J. Study of combined technetium 99m methylene diphosphonate and gallium 67 citrate scintigraphy in diffuse sclerosing osteomyelitis of the mandible: case reports. J Oral Maxillofac Surg. 1991;49(8):887–97. PubMed PMID: 2072205.PubMedGoogle Scholar
  96. 96.
    Ubios AM, Braun EM, Cabrini RL. Lethality due to uranium poisoning is prevented by ethane-1-hydroxy-1,1-biphosphonate (EHBP). Health Phys. 1994;66(5):540–4. PubMed PMID: 8175360.PubMedGoogle Scholar
  97. 97.
    Ubios AM, Braun EM, Cabrini RL. Effect of biphosphonates on abnormal mandibular growth of rats intoxicated with uranium. Health Phys. 1998;75(6):610–3. PubMed PMID: 9827507.PubMedGoogle Scholar
  98. 98.
    van Dyck M, Proesmans W, van Hollebeke E, Marchal G, Moerman P. Idiopathic infantile arterial calcification with cardiac, renal and central nervous system involvement. Eur J Pediatr. 1989;148(4):374–7. PubMed PMID: 2707283.PubMedGoogle Scholar
  99. 99.
    Veena HR, Prasad D. Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects. J Indian Soc Periodontol. 2010;14(1):40–5. PubMed PMID: 20922078.PubMedCentralPubMedGoogle Scholar
  100. 100.
    Volpe AR, Petrone ME, Davies RM. A review of calculus clinical efficacy studies. J Clin Dent. 1993;4(3):71–81. PubMed PMID: 8003237.PubMedGoogle Scholar
  101. 101.
    Wang K, Allen L, Fung E, Chan CC, Chan JCS, Griffith JF. Bone scintigraphy in common tumors with osteolytic components. Clin Nucl Med. 2005;30(10):655–71. PubMed PMID: 16166837.PubMedGoogle Scholar
  102. 102.
    Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, Chaves E, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res. 1994;29(1):35–40. PubMed PMID: 8113951.PubMedGoogle Scholar
  103. 103.
    White DJ, Cox ER. In vitro studies of the anticalculus efficacy of an improved whitening dentifrice. J Clin Dent. 2001;12(2):38–41. PubMed PMID: 11476012.PubMedGoogle Scholar
  104. 104.
    White DJ, Cox ER, Suszcynskymeister EM, Baig AA. In vitro studies of the anticalculus efficacy of a sodium hexametaphosphate whitening dentifrice. J Clin Dent. 2002;13(1):33–7. PubMed PMID: 11507930.PubMedGoogle Scholar
  105. 105.
    White DJ, Gerlach RW. Anticalculus effects of a novel, dual-phase polypyrophosphate dentifrice: chemical basis, mechanism, and clinical response. J Contemp Dent Pract. 2000;1(4):1–19. PubMed PMID: 12167947.PubMedGoogle Scholar
  106. 106.
    Wright SA, Millar AM, Coward SM, Finch MB. Chronic diffuse sclerosing osteomyelitis treated with risedronate. J Rheumatol. 2005;32(7):1376–8. PubMed PMID: 15996085.PubMedGoogle Scholar
  107. 107.
    Xiong H, Peng B, Wei L, Zhang X, Wang L. Effect of an estrogen-deficient state and alendronate therapy on bone loss resulting from experimental periapical lesions in rats. J Endod. 2007;33(11):1304–8. PubMed PMID: 17963952.PubMedGoogle Scholar
  108. 108.
    Xu K, Ge W, Liang G, Wang L, Yang Z, Wang Q, et al. Bisphosphonate-containing supramolecular hydrogels for topical decorporation of uranium-contaminated wounds in mice. Int J Radiat Biol. 2008;84(5):353–62. PubMed PMID: 18464065.PubMedGoogle Scholar
  109. 109.
    Yamamoto-Silva FP, Bradaschia-Correa V, Lima LAPA, Arana-Chavez VE. Ultrastructural and immunohistochemical study of early repair of alveolar sockets after the extraction of molars from alendronate-treated rats. Microsc Res Tech. 2013;76(6):633–40. PubMed PMID: 23564359.PubMedGoogle Scholar
  110. 110.
    Yamazaki Y, Satoh C, Ishikawa M, Notani K, Nomura K, Kitagawa Y. Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(1):67–71. PubMed PMID: 17197211.PubMedGoogle Scholar
  111. 111.
    Yoshinari M, Oda Y, Inoue T, Matsuzaka K, Shimono M. Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials. 2002;23(14):2879–85. PubMed PMID: 12069328.PubMedGoogle Scholar
  112. 112.
    Zhao X, Yan S. Recent progress in osteogenesis imperfecta. Orthop Surg. 2011;3(2):127–30. PubMed PMID: 22009598.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ralf Smeets
    • 1
  • Henning Hanken
    • 1
  • Ole Jung
    • 1
  • Max Heiland
    • 1
  1. 1.Department of Oral and Maxillofacial SurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations